Suppliers / Biological E

Biological E

India 243 employees 3 duplicate records merged Updated 9 July 2026

Biological E is a finished-dose manufacturer based in India. It appears in 62 regulatory filings across 12 regulators, without an active US DMF or CEP on file. Its filings concentrate with EDE (AE), MCAZ (ZW) and COFEPRIS (MX). Its GMP standing is certified by ANVISA (Brazil), FDA (GH) and CDSCO (India), among 7 authorities. Its most recent recorded inspection, by US FDA, closed on 12 November 2024 as VAI. Customs aggregates show $350.7M of exports covering 1,175 molecules to 112 destinations in 2025.

0
active US DMFs
0
valid CEPs
5
registered plants 2 with an FDA FEI number
62
filings across 12 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
4 of 4 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 12 November 2024 VAI US FDA
  • 26 April 2024 VAI US FDA
  • 2 August 2019 VAI US FDA
  • 6 March 2019 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Medchal, United Arab Emirates Not on file
Medchal, India 3009522832
Medchal, India 3008377265
TELANGANA, India Not on file
Medchal Malkajgiri, India Not on file

Filings and GMP by regulator

Regulator Filings GMP certificates
EDE (AE) 29 None
MCAZ (ZW) 8 None
COFEPRIS (MX) 3 None
JFDA (JO) 3 None
NMRC (NA) 3 None
NAFDAC (NG) 3 1
ANVISA (Brazil) None 4
FDA (GH) None 2
CDSCO (India) None 2
EMA None 2
MHRA (UK) None 1
US FDA None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $32.1M 54
2025 Not reported $350.7M 112
2024 Not reported $224.8M 120
2023 Not reported $181.9M 116

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Biological E comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 12 November 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts